CONVIDECIA



Product Overview


Type:                                     COVID-19 Vaccine (Ad5-nCoV-S [Recombinant]) 


INN:                                       N/A


Commercial name:              Convidecia


EUL holder:                          CanSino Biologics Inc.


Country:                                People’s Republic of China


Responsible NRA:                National Medical Products Administration (NMPA)  


Country:                                People’s Republic of China


 

WHO EUL recommendation


Effective date:           19 May 2022


Recommendation for an Emergency Use Listing (EUL) of Convidecia COVID-19 Vaccine (Ad5/nCoV-5[recombinant]) submitted by CanSino Biologics Inc. (Published: 10 October 2022)


 

Product description


Pharmaceutical Form:            Sterile solution for injection


Presentation:                            2 mLVial


Number of doses:                     1 and 3 doses of 0.5 mL


Route of administration:         Intramuscular


Age indication:                         Individuals 18 to 59 years of age


Shelf – life:                                12 months


Storage temperature:               2°C to 8°C


Vaccine Vial monitor (VVM):  None


Preservative:                              None


Diluent:                                         None


Special storage conditions:     Not applicable


Handling of opened multi-dose vials: 

WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first.


 

Packaging description

Secondary Packaging:

Box containing 40 vials (40 doses). Dimensions: 4.4 x 15.6 x 9.5 cm

Tertiary Packaging:

a. Carton containing 18 secondary boxes (58 vials/720 doses). Dimensions: 17x49.3x21.7 cm.

b. Carton containing 30 secondary boyes (1200 vials/1200 doses). Dimensions: 25.5x34x31.5 cm. 

Cold Chain Volume: 16.30 cm3/dose      (in secondary packaging)